

FEDERAL REGISTER INDEX

January–May 2022

Food and Drug Administration

RULES

Beverages:

Bottled Water – 23434 (Apr 20)

Change of Name and Function:

Bone, Reproductive and Urologic Drugs Advisory Committee; Technical Amendment – 16393 (Mar 23)

Current Good Manufacturing Practice and Preventive Controls, Foreign Supplier Verification Programs, Intentional Adulteration, and Produce Safety Regulations:

Enforcement Policy Regarding Certain Provisions; Guidance for Industry – 14169 (Mar 14)

Food Additives Permitted in Feed and Drinking Water of Animals:

Methyl Esters of Conjugated Linoleic Acid – 21018 (Apr 11)

Food Additives; CFR Correction – 17941 (Mar 29)

Food Labeling; CFR Correction – 16983 (Mar 25)

Guidance:

Certain Ophthalmic Products, Policy Regarding Compliance – 16391 (Mar 23)

Importation of Prescription Drugs Final Rule Questions and Answers – 31954 (May 26)

Initiation of Voluntary Recalls – 12401 (Mar 4)

Indirect Food Additives:

Adhesives and Components of Coatings; Paper and Paperboard Components; Polymers; Adjuvants, Production Aids, and Sanitizers – 31080 (May 20)

Laboratory Accreditation for Analyses of Foods; Correction – 5660 (Feb 2)

Listing of Color Additives Exempt from Certification:

Antarctic Krill Meal – 27931 (May 10)

Medical Devices:

Cardiovascular Devices; Classification of the Adjunctive Predictive Cardiovascular Indicator – 8190 (Feb 14)

Cardiovascular Devices; Classification of the Electrocardiograph Software for Over-the-Counter Use – 2547 (Jan 18)

Cardiovascular Devices; Classification of the Percutaneous Catheter for Creation of an Arteriovenous Fistula for Hemodialysis Access – 9240 (Feb 18)

Cardiovascular Devices; Classification of the Photoplethysmograph Analysis Software for Over-the-Counter Use – 6417 (Feb 4)

Cardiovascular Devices; Classification of the Reverse Central Venous Recanalization System – 26989 (May 6)

Clinical Chemistry and Clinical Toxicology Devices; Classification of the Integrated Continuous Glucose Monitoring System – 9237 (Feb 18)

Clinical Chemistry and Clinical Toxicology Devices; Classification of the Interoperable Automated Glycemic Controller – 14171 (Mar 14)

Gastroenterology-Urology Devices; Classification of the Magnetically Maneuvered Capsule Endoscopy System – 26991 (May 6)

General and Plastic Surgery Devices; Classification of the Autofluorescence Detection Device for General Surgery and Dermatological Use – 24271 (Apr 25)

General and Plastic Surgery Devices; Classification of the Carbon Dioxide Gas Controlled Tissue Expander – 6419 (Feb 4)

General and Plastic Surgery Devices; Classification of the Mountable Electromechanical Surgical System for Transluminal Approaches – 26993 (May 6)

General Hospital and Personal Use Devices; Classification of the Alternate Controller Enabled Infusion Pump – 6422 (Feb 4)

General Hospital and Personal Use Devices; Classification of the Spore Test Strip – 8192 (Feb 14)

Immunology and Microbiology Devices; Classification of the System for Detection of Microorganisms and Antimicrobial Resistance Using Reporter Expression – 6415 (Feb 4)

Ophthalmic Devices; Classification of the Electromechanical Tear Stimulator – 9242 (Feb 18)

Ophthalmic Devices; Classification of the Retinal Diagnostic Software Device – 3203 (Jan 21)

Orthopedic Devices; Classification of the Screw Sleeve Bone Fixation Device – 11293 (Mar 1)

Technical Amendments – 17949 (Mar 29)

Microbiology Devices:

Reclassification of Human Immunodeficiency Virus Serological Diagnostic and Supplemental Tests and HIV Nucleic Acid Diagnostic and Supplemental Tests – 29661 (May 16)

New Animal Drugs:

Approval of Applications; Change of Sponsor – 17942 (Mar 29)

Approval of New Animal Drug Applications; Withdrawal of Approval of a New Animal Drug Application; Change of Sponsor – 10964 (Feb 28)

New Method for the Analysis of Suites in Foods – 2542 (Jan 18)

Petition for an Administrative Stay of Action:

Milk and Cream; Definitions and Standards of Identity for Yogurt, Lowfat Yogurt, and Nonfat Yogurt – 16394 (Mar 23)

Procedures for the Announcement of Approvals and Denials of Premarket Approval Applications and Humanitarian Device Exemption Applications – 2042 (Jan 13)

Revocation of a Standard of Identity:

French Dressing – 2038 (Jan 13)

Revocation of the Regulations for Human Tissue Intended for

Transplantation and Human Dura Mater – 2045 (Jan 13)

Securing Updated and Necessary Statutory Evaluations Timely; Administrative Delay of Effective Date – 12399 (Mar 4)

Securing Updated and Necessary Statutory Evaluations Timely; Withdrawal – 32246 (May 27)

Tobacco Products:

Required Warnings for Cigarette Packages and Advertisements; Delayed Effective Date – 11295 (Mar 1)

PROPOSED RULES

Certain Requirements Regarding Prescription Drug Marketing – 6443 (Feb 4)

Current Good Manufacturing Practice, Certification, Postmarketing Safety Reporting, and Labeling Requirements for Certain Medical Gases – 31302 (May 23)

Filing of Color Additive Petition:

Motif FoodWorks, Inc. – 8222 (Feb 14)

Filing of Food Additive Petition (Animal Use):

Anitox Corp. – 21069 (Apr 11)

Food Additive Petition:

Natural Resources Defense Council, et al.; Denial – 31066 (May 20)

Ranks, Hovis, McDougall Research, Ltd.; Withdrawal – 26707 (May 5)

Food Additives:

Food Contact Substance Notification That Is No Longer Effective – 3949 (Jan 26)

Guidance:

Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements – 31440 (May 24)

The Accredited Third-Party Certification Program: Questions and Answers – 25432 (Apr 29)

Hearings:

Scientific Data and Information Related to the Residue of Carcinogenic Concern for the New Animal Drug Carbadox – 18750 (Mar 31)

Medical Devices:

Immunology and Microbiology Devices; Classification of Human Leukocyte, Neutrophil and Platelet Antigen and Antibody Tests – 3250 (Jan 21)

Quality System Regulation – 10119 (Feb 23)

National Standards for the Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers – 6708 (Feb 4); 31439 (May 24)

Food and Drug Administration

Policy Regarding Certain New Dietary Ingredients and Dietary Supplements Subject to the Requirement for Pre-Market Notification:
Draft Guidance for Industry; Agency Information Collection Activities; etc. – 30843 (May 20)

Removal of Certain Requirements Related to the Prescription Drug Marketing Act; Withdrawal – 6449 (Feb 4)

Scientific Data and Information Related to the Residue of Carcinogenic Concern for the New Animal Drug Carbadox – 2093 (Jan 13)

Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption Relating to Agricultural Water – 913 (Jan 7)

Tobacco Product Standard:
Characterizing Flavors in Cigars – 26396 (May 4)
Menthol in Cigarettes – 26454 (May 4)
Menthol in Cigarettes and Characterizing Flavors in Cigars; Listening Sessions and Public Meeting – 26311 (May 4)

NOTICES

21st Century Cures Act:
Annual Compilation of Notices of Updates from the Susceptibility Test Interpretive Criteria Web Page – 4612 (Jan 28)

Abbreviated New Drugs:
Fresenius Kabi USA, LLC, et al.; Applications: Withdrawal of Approval – 11079 (Feb 28)

Agency Information Collection Activities; Proposals, Submissions, and Approvals – 4628 (Jan 28); 12175 (Mar 3); 20432 (Apr 7); 28016 (May 10)

Agency Information Collection Activities; Proposals, Submissions, and Approvals:
Abbreviated New Animal Drug Applications – 15436 (Mar 18)
Accelerated Approval Disclosures on Direct-to-Consumer Prescription Drug Websites – 16743 (Mar 24)
Accreditation of Third-Party Certification Bodies to Conduct Food Safety Audits and Issue Certifications – 8846 (Feb 16)
Administrative Detention and Banned Medical Devices – 26208 (May 3)
Agreement for Shipment of Devices for Sterilization – 14540 (Mar 15)
Antimicrobial Animal Drug Distribution Reports and Recordkeeping – 26764 (May 5)
Authorization for Medical Products for Use in Emergencies – 12175 (Mar 3)
Center for Devices and Radiological Health Appeals Processes – 9365 (Feb 18)
Class II Special Controls for HIV Serological Diagnostic and Supplemental Tests and HIV Nucleic Acid Diagnostic and Supplemental Tests – 9057 (Feb 17)
Current Good Manufacturing Practices for Positron Emission Tomography Drugs – 20420 (Apr 7)
Drug Supply Chain Security Act Implementation – 1419 (Jan 11)
Environmental Impact Considerations – 6872 (Feb 7)
Establishing and Maintaining Lists of United States Establishments with Interest in Exporting Center for Food Safety and Applied Nutrition-Regulated Products – 3814 (Jan 25)
Establishing That a Tobacco Product Was Commercially Marketed in the United States as of February 15, 2007 – 26209 (May 3)
Establishment Registration and Device Listing for Manufacturers and Importers of Devices – 7187 (Feb 8)
Exemptions from Substantial Equivalence Requirements for Tobacco Products – 10797 (Feb 25)
Expanded Access to Investigational Drugs for Treatment Use – 25282 (Apr 28)
Export Notification and Recordkeeping Requirements – 24321 (Apr 25)
Export of Medical Devices; Foreign Letters of Approval – 4609 (Jan 28)
Exports Notification and Recordkeeping Requirements – 3811 (Jan 25)
Financial Disclosure by Clinical Investigators – 18371 (Mar 30)
Food Contact Substance Notification Program – 7190 (Feb 8)
Foreign Supplier Verification Programs for Food Importers – 4607 (Jan 28); 21126 (Apr 11)
Generic Clearance for Quick Turnaround Testing of Communication Effectiveness – 22906 (Apr 18)
Generic Drug User Fee Program – 7473 (Feb 9)
Guidance on Meetings with Industry and Investigators on the Research and Development of Tobacco Products – 5824 (Feb 2)
Guidance on Reagents for Detection of Specific Novel Influenza A Viruses – 3812 (Jan 25)
Interstate Shellfish Dealer's Certificate and Participation in the National Shellfish Sanitation Program – 27650 (May 9)
Investigational Device Exemptions – 27168 (May 6)
Investigational New Drug Application Regulations – 9058 (Feb 17)

Manufactured Food Regulatory Program Standards – 2162 (Jan 13)

Medical Device Accessories – 14891 (Mar 16)

Medical Device User Fee Small Business Qualification and Certification – 24310 (Apr 25)

Medical Devices; Humanitarian Use Devices – 20429 (Apr 7)

Medicated Feed Mill License Application – 4620 (Jan 28); 26210 (May 3)

Medication Guides for Prescription Drug Products – 16199 (Mar 22)

MedWatch: Safety Information and Adverse Event Reporting Program – 14894 (Mar 16)

New Animal Drug Applications and Veterinary Master Files – 11713 (Mar 2)

New Molecular Entity New Drug Applications and Original Biologics License Applications – 16006 (Mar 21)

Obtaining Information To Understand Challenges and Opportunities Encountered by Compounding Outsourcing Facilities – 228 (Jan 4)

Postmarket Surveillance of Medical Devices – 32169 (May 27)

Premarket Tobacco Product Applications and Recordkeeping Requirements – 29749 (May 16)

Prescription Drug User Fee Program – 7186 (Feb 8)

Prevention of Salmonella Enteritidis in Shell Eggs During Production; Recordkeeping and Registration Provisions – 2797 (Jan 19)

Public Health Service Guideline on Infectious Disease Issues in Xenotransplantation – 24316 (Apr 25)

Quantitative Research on a Voluntary Symbol Depicting the Nutrient Content Claim "Healthy" on Packaged Foods – 17300 (Mar 28)

Quantitative Testing for the Development of Communications – 4625 (Jan 28)

Recordkeeping Requirements for Microbiological Testing and Corrective Measures for Bottled Water – 3818 (Jan 25)

Registration and Product Listing for Owners and Operators of Domestic Tobacco Product Establishments and Listing of Ingredients in Tobacco Products – 4622 (Jan 28)

Registration of Food Facilities – 2159 (Jan 13)

Reporting Associated with Food Additive Petitions, Investigational Food Additive Files Exemptions, and Declaration of Color Additives on Animal Food Labels – 4614 (Jan 28)

Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke under the Federal Food, Drug, and Cosmetic Act – 6869 (Feb 7)

Sanitary Transportation of Human and Animal Food – 10369 (Feb 24)

Study of How Consumers Use Flavors to Make Inferences about Electronic Nicotine Delivery System Product Qualities and Intentions to Use (Phase 2) – 9067 (Feb 17)

Substances Prohibited from Use in Animal Food or Feed; Animal Proteins Prohibited in Ruminant Feed – 4626 (Jan 28)

Threshold of Regulation for Substances Used in Food-Contact Articles – 20433 (Apr 7)

Tobacco Health Document Submission – 10800 (Feb 25)

Tobacco Products Subject to the Federal Food, Drug, and Cosmetic Act – 25280 (Apr 28)

Tobacco Retailer Training Programs – 26766 (May 5)

Tradeoff Analysis of Prescription Drug Product Claims in Direct-to-Consumer and Healthcare Provider Promotion – 24313 (Apr 25)

Warning Plans for Smokeless Tobacco Products – 27644 (May 9)

Antimicrobial Drug Use in Companion Animals – 8848 (Feb 16)

Charter Amendments, Establishments, Renewals and Terminations:
Anesthetic and Analgesic Drug Products Advisory Committee – 26762 (May 5)
Gastrointestinal Drugs Advisory Committee – 28834 (May 11)
Gastrointestinal Drugs Advisory Committee; Correction – 31245 (May 23)
Pharmaceutical Science and Clinical Pharmacology Advisory Committee – 25277 (Apr 28)
Vaccines and Related Biological Products Advisory Committee – 4897 (Jan 31)

Charter Renewal:
Obstetrics, Reproductive and Urologic Drugs Advisory Committee – 16477 (Mar 23)

Complaint:
Patent Infringement against a Biosimilar or Interchangeable Biosimilar Applicant – 7844 (Feb 10)

Data Standards:
Version 3.1.1 of the Clinical Data Interchange Standards Consortium Standard for Exchange of Nonclinical Data Implementation Guide – 8585 (Feb 15)

Determination:

- MPI DMSA KIDNEY REAGENT (Technetium Tc-99m Succimer Kit), Injectable, was Not Withdrawn from Sale for Reasons of Safety or Effectiveness – 14272 (Mar 14)
- Drug Application:
Hospira, Inc., et al.; Withdrawal of Approval – 30962 (May 20)
TG Therapeutics, Inc.; Ukoniq (Umbalisib Tosylate) Tablets, Equivalent to 200 Milligrams Base: Withdrawal of Approval – 32425 (May 31)
- Drug Products not Withdrawn from Sale for Reasons of Safety or Effectiveness:
Cupric Sulfate Injection, Equivalent to 0.4 Milligram Copper/Milliliter – 25493 (Apr 29)
Folvite (Folic Acid), Oral Tablets, 1 Milligram, and Other Drug Products – 25028 (Apr 27)
NASONEX (Mometasone Furoate) Nasal Spray, 0.05 Milligram/Spray (50 Microgram) – 20875 (Apr 8)
Pepcid (Famotidine) Tablet, 20 Milligrams and 40 Milligrams – 2616 (Jan 18)
Totect (Dexrazoxane Hydrochloride) for Injection, 500 Milligrams – 21891 (Apr 13)
- Drug Products Not Withdrawn from Sale for Reasons of Safety or Effectiveness:
Glucotrol (Glipizide) Tablets, 2.5 Milligrams – 28015 (May 10)
Pepcid (Famotidine) for Oral Suspension, 40 Milligrams/5 Milliliters – 20419 (Apr 7)
- Drugs for Human Use; Drug Efficacy Study Implementation:
Oral Prescription Drugs Containing an Anticholinergic or Antispasmodic in Combination with a Sedative, and Single-Entity Antispasmodic Drug Products, in Oral Dosage Form – 24311 (Apr 25)
- Emergency Use Authorization:
Biological Product during the COVID-19 Pandemic – 16201 (Mar 22)
Certain Drugs and Biological Products during the COVID-19 Pandemic – 6578 (Feb 4)
Certain Medical Devices during COVID-19 – 16196 (Mar 22)
In Vitro Diagnostic Device for Detection and/or Diagnosis of COVID-19; Revocation – 31565 (May 24)
In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19 – 2163 (Jan 13)
In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Revocation – 3306 (Jan 21); 12459 (Mar 4); 14273 (Mar 14); 22900 (Apr 18)
- Final Debarment Order:
Brenda K. Marmas – 7840 (Feb 10)
Brian Michael Parks – 8264 (Feb 14)
Eduardo Navarro – 12171 (Mar 3)
George Kuiper – 12174 (Mar 3)
Howard Stanley Head, Jr. – 29867 (May 17)
Irfanali Nisarali Momin – 16214 (Mar 22)
Lisett Raventos – 22218 (Apr 14)
Marwan Massouh – 28834 (May 11)
Nayade Varona – 14539 (Mar 15)
Patrick Charles Bishop – 12172 (Mar 3)
Shiba I. Momin – 16215 (Mar 22)
William Kulakevich – 225 (Jan 4)
Yvelice Villaman-Bencosme – 23184 (Apr 19)
- Food and Drug Administration Modernization Act:
Modifications to the List of Recognized Standards, Recognition List Number: 057 – 24175 (Apr 22)
- Guidance for Industry; Availability:
Reducing Microbial Food Safety Hazards in the Production of Seed for Sprouting – 29753 (May 16)
- Guidance:
Action Levels for Lead in Juice – 25491 (Apr 29)
Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues – 32171 (May 27)
Antibacterial Therapies for Patients with an Unmet Medical Need for the Treatment of Serious Bacterial Diseases--Questions and Answers (Revision 1) – 31568 (May 24)
Appeal Options Available to Mammography Facilities Concerning Adverse Accreditation Decisions, Suspension/Revocation of Certificates, etc. – 11712 (Mar 2)
Assessing the Credibility of Computational Modeling and Simulation in Medical Device Submissions – 4611 (Jan 28)
Assessing User Fees under the Generic Drug User Fee Amendments of 2017 – 30229 (May 18)
- Assessment of Pressor Effects of Drugs – 6577 (Feb 4)
Benefit-Risk Considerations for Product Quality Assessments – 28016 (May 10)
Bioavailability Studies Submitted in New Drug Applications or Investigational New Drug Applications--General Considerations – 22537 (Apr 15)
Blood Pressure and Pulse Donor Eligibility Requirements: Compliance Policy – 31567 (May 24)
Celiac Disease: Developing Drugs for Adjunctive Treatment to a Gluten-Free Diet – 22536 (Apr 15)
Chronic Hepatitis B Virus Infection: Developing Drugs for Treatment – 20431 (Apr 7)
Clinical Pharmacology Considerations for Antibody-Drug Conjugates – 7184 (Feb 8)
Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies – 26763 (May 5)
Collecting and Providing Portions of Official Samples – 3302 (Jan 21)
Compliance Policy Guide, Scombrototoxin (Histamine)-Forming Fish and Fishery Products--Decomposition and Histamine – 14538 (Mar 15)
Compliance Policy Guides; Withdrawal – 24174 (Apr 22)
Compounding Animal Drugs from Bulk Drug Substances – 22212 (Apr 14)
Considerations for the Development of Chimeric Antigen Receptor T Cell Products – 14893 (Mar 16)
Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic Use – 22217 (Apr 14)
Coronavirus Disease 2019 – 3303 (Jan 21); 12461 (Mar 4); 24172 (Apr 22)
Crohn's Disease: Developing Drugs for Treatment – 25494 (Apr 29)
Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions – 20873 (Apr 8)
Development of Non-Opioid Analgesics for Acute Pain – 7843 (Feb 10)
Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials – 22211 (Apr 14)
Drug Product Tracing: The Effect of Section 585 of the Federal Food, Drug, and Cosmetic Act, Questions and Answers – 6572 (Feb 4)
Drug Products, Including Biological Products, That Contain Nanomaterials – 24169 (Apr 22)
E8(R1) General Considerations for Clinical Studies; International Council for Harmonisation – 21127 (Apr 11)
Evaluating the Public Health Importance of Food Allergens other than the Major Food Allergens Listed in the Federal Food, Drug, and Cosmetic Act – 23181 (Apr 19)
Expansion Cohorts: Use in First-in-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics – 11720 (Mar 2)
Feasibility and Early Feasibility Clinical Studies for Certain Medical Devices Intended to Therapeutically Improve Glycemic Control in Patients with Type 2 Diabetes Mellitus – 27170 (May 6)
Formal Meetings between the Food and Drug Administration and Sponsors or Requestors of Over-the-Counter Monograph Drugs – 6877 (Feb 7)
Fostering Medical Device Improvement: Food and Drug Administration Activities and Engagement with the Voluntary Improvement Program – 27165 (May 6)
Good Abbreviated New Drug Applications Submission Practices – 4255 (Jan 27)
Human Gene Therapy Products Incorporating Human Genome Editing – 14897 (Mar 16)
Immunogenicity Information in Human Prescription Therapeutic Protein and Select Drug Product Labeling – 6574 (Feb 4)
Inclusion of Older Adults in Cancer Clinical Trials – 11718 (Mar 2)
Information Requests and Discipline Review Letters under Generic Drug User Fee Amendments – 4257 (Jan 27)
M7(R2) Addendum: Application of the Principles of the ICH M7 Guideline to Calculation of Compound-Specific Acceptable Intakes; International Council for Harmonisation – 20435 (Apr 7)
Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics – 11722 (Mar 2)
Nonclinical Considerations for Mitigating Nonhuman Primate Supply Constraints Arising from the COVID-19 Pandemic – 10373 (Feb 24)
Notifying the Food and Drug Administration of a Permanent Discontinuance or Interruption in Manufacturing of a Device under Section 506j of the Federal Food, Drug, and Cosmetic Act – 6875 (Feb 7)

Food and Drug Administration

- Patient Engagement in the Design and Conduct of Medical Device Clinical Studies – 4036 (Jan 26)
- Patient-Focused Drug Development: Methods to Identify What is Important to Patients – 11077 (Feb 28)
- Performance Criteria for Safety and Performance Based Pathway – 21889 (Apr 13)
- Permanent Discontinuance or Interruption in Manufacturing of a Device under the Federal Food, Drug, and Cosmetic Act: – 1417 (Jan 11)
- Policy Regarding N-acetyl-L-cysteine – 24170 (Apr 22)
- Population Pharmacokinetics – 6575 (Feb 4)
- Practices to Prevent Unsafe Contamination of Animal Feed from Drug Carryover – 28018 (May 10)
- Pre-Launch Activities Importation Requests – 11716 (Mar 2)
- Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation – 4033 (Jan 26)
- Principles of Premarket Pathways for Combination Products – 4895 (Jan 31)
- Product-Specific Guidance for Testosterone – 27162 (May 6)
- Product-Specific Guidances – 9366 (Feb 18); 30961 (May 20)
- Providing Submissions in Electronic Format--Postmarketing Safety Reports – 25278 (Apr 28)
- Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components – 31563 (May 24)
- Reconditioning of Fish and Fishery Products by Segregation – 22221 (Apr 14)
- Revising Abbreviated New Drug Application Labeling Following Revision of the Reference Listed Drug Labeling – 4252 (Jan 27)
- Risk Management Plans to Mitigate the Potential for Drug Shortages – 30963 (May 20)
- Safety and Performance Based Pathway Device-Specific Guidances – 21124 (Apr 11)
- Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors – 30227 (May 18)
- Ulcerative Colitis: Developing Drugs for Treatment – 25490 (Apr 29)
- Use of Circulating Tumor Deoxyribonucleic Acid for Early-Stage Solid Tumor Drug Development – 26207 (May 3)
- Use of Published Literature in Support of New Animal Drug Applications – 23523 (Apr 20)
- Use of Tracers in Animal Food, Type A Medicated Articles, and Medicated Feeds – 11719 (Mar 2)
- Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Questions and Answers – 20872 (Apr 8)
- Verification Systems under the Drug Supply Chain Security Act for Certain Prescription Drugs – 13738 (Mar 10)
- Verification Systems under the Drug Supply Chain Security Act for Certain Prescription Drugs; Correction – 16217 (Mar 22)
- List:
- Bulk Drug Substances of Which There Is a Clinical Need under the Federal Food, Drug, and Cosmetic Act – 4240 (Jan 27)
- Medical Devices:
- 510(k) Sterility Change Master File Pilot Program – 30957 (May 20)
- Meetings:
- Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee – 226 (Jan 4)
- Cellular, Tissue and Gene Therapies Advisory Committee – 8850 (Feb 16); 22215 (Apr 14)
- Cellular, Tissue, and Gene Therapies Advisory Committee – 32422 (May 31)
- Device Good Manufacturing Practice Advisory Committee – 9066 (Feb 17)
- Final Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act – 10371 (Feb 24)
- Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments – 29161 (May 12)
- Fiscal Year 2022 Generic Drug Science and Research Initiatives Workshop – 8843 (Feb 16)
- Food and Drug Administration Hiring and Retention Final Assessment – 8262 (Feb 14)
- General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee – 32172 (May 27)
- Medical Device User Fee Amendments – 20436 (Apr 7)
- Oncologic Drugs Advisory Committee; Establishment of a Public Docket – 13736 (Mar 10)
- Patient Engagement Advisory Committee – 22220 (Apr 14)
- Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee – 20418 (Apr 7)
- Peripheral and Central Nervous System Drugs Advisory Committee – 9064 (Feb 17)
- Pharmacy Compounding Advisory Committee – 27163 (May 6)
- Prescription Drug User Fee Act of 2017; Electronic Submissions and Data Standards – 4254 (Jan 27)
- Psychopharmacologic Drugs Advisory Committee; Establishment of a Public Docket – 26212 (May 3)
- Science Board to the Advisory Committee – 30226 (May 18)
- Toxicological Research Advisory Committee – 23522 (Apr 20)
- Vaccines and Related Biological Products Advisory Committee – 3817 (Jan 25); 6571 (Feb 4); 16216 (Mar 22); 32418, 32420, 32423 (May 31)
- New Animal Drugs:
- New Animal Drug Application; Withdrawal of Approval – 11079 (Feb 28)
- Over-the-Counter Monograph Drug User Fee Rates for Fiscal Year 2022 – 14888 (Mar 16)
- Patent Extension Regulatory Review Period:
- Enhertu; Correction – 1762 (Jan 12)
- Permits:
- Grated Parmesan Cheese Deviating from Identity Standard; Amendment of Temporary Marketing Permit – 27161 (May 6)
- Pharmaceutical Quality/Chemistry Manufacturing and Controls Data Exchange – 15435 (Mar 18)
- Prescription Drug User Fee Rates for Fiscal Year 2022; Correction – 17300 (Mar 28)
- Prioritizing the Addition of Maximum Daily Exposure Information and Removing Dosage Form Information From the Inactive Ingredient Database – 16212 (Mar 22)
- Priority Review Voucher:
- Material Threat Medical Countermeasure Product – 9057, 9064 (Feb 17); 25491 (Apr 29); 25645 (May 2)
- Prospective Grant of Exclusive Patent License:
- A Diagnostic Tool Based Upon Magnetic Resonance Spectroscopy Pre-Processing and Renormalization – 92 (Jan 3)
- Providing Mail-Back Envelopes and Education on Safe Disposal with Opioid Analgesics Dispensed in an Outpatient Setting – 23869 (Apr 21)
- Quality Metrics Reporting Program:
- Establishment of a Public Docket – 13295 (Mar 9)
- Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments – 23868 (Apr 21)
- Request for Comments:
- International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; World Health Organization; etc. – 8586 (Feb 15)
- Request for Information:
- Ortho-Phthalates for Food Contact Use – 31090 (May 20)
- Requests for Nominations:
- Individuals and Consumer Organizations for Advisory Committees – 4616 (Jan 28)
- List of Bulk Drug Substances for Compounding: Office Stock Drugs for Use in Nonfood-Producing Animals or Drugs for Use in Food-Producing Animals or Free-Ranging Wildlife Species – 22222 (Apr 14)
- Pediatric Advisory Committee – 25276 (Apr 28)
- Public Advisory Panels of the Medical Devices Advisory Committee – 93 (Jan 3)
- Technical Electronic Product Radiation Safety Standards Committee – 8845 (Feb 16)
- Revocation of Authorization of Emergency Use:
- In Vitro Diagnostic Device for Detection and/or Diagnosis of COVID-19 – 16005 (Mar 21)
- Revocation of Emergency Use Authorization:
- In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19 – 27646 (May 9)
- Statement of Organization, Functions, and Delegations of Authority – 89, 94, 95 (Jan 3)
- Withdrawal of Approval of 14 Abbreviated New Drug Applications:
- Baxter Healthcare Corporation, et al. – 24320 (Apr 25)
- Withdrawal of Approval of Drug Application:
- Acrotech Biopharma, LLC; MARQIBO (VinCRISTine Sulfate LIPOSOME Injection), 5 milligrams/5 milliliters – 25644 (May 2)

Celgene Corporation and Teva Pharmaceutical Industries, Ltd.; Peripheral T-Cell Lymphoma Indication for ISTODAX (Romidepsin) for Injection and Romidepsin Injection – 27644 (*May 9*)
Fresenius Kabi USA, LLC, et al.; Correction – 23184 (*Apr 19*)
Fresenius USA, Inc., et al.; Correction – 2616 (*Jan 18*)
Hikma Pharmaceuticals USA, Inc., et al. – 5827 (*Feb 2*)
Potassium Aminobenzoate Oral Preparations – 13294 (*Mar 9*)
Secura Bio, Inc.; Farydak (Panobinostat) Capsules, 10 Milligrams, 15 Milligrams, and 20 Milligrams – 16742 (*Mar 24*)
Watson Laboratories, Inc., et al. – 5828 (*Feb 2*)

Withdrawal of Approval of Indications for Relapsed Follicular Lymphoma and Relapsed Small Lymphocytic Lymphoma:
Gilead Sciences, Inc.; Zydelig (Idelalisib) Tablets – 32031 (*May 26*)
Withdrawal of Approval of Relapsed or Refractory Follicular Lymphoma Indication:
Secura Bio, Inc.; Copiktra – 21888 (*Apr 13*)
Withdrawal of Guidance:
Compliance Policy Guide Sec. 510.800, 540.420, 562.800 – 8592 (*Feb 15*)